| Category | Score (1–10) | Justification |
|---|---|---|
| Facts | 9 | Backed by FDA approvals, peer-reviewed trials, and up-to-date regulatory data |
| Source Credibility | 10 | All data drawn from official government, academic, and clinical research institutions |
| Impartiality | 10 | Clearly explains both benefits and risks without promoting commercial use |
| Ownership | 10 | Public educational content with no commercial affiliation or sponsorship |
| Author | 10 | Transparent synthesis from expert sources, with references cited |
Ozempic (Semaglutide): Overview of Science
Ozempic (semaglutide) is a once-weekly injectable approved by the FDA to manage type 2 diabetes and reduce cardiovascular risk. Under the brand Wegovy, a higher dose of semaglutide is also approved for chronic weight management in adults and adolescents with obesity or overweight and related conditions.
How It Works
Ozempic mimics the gut hormone GLP-1, stimulating insulin release, reducing glucose production, slowing digestion, and decreasing appetite. This helps lower A1c levels and supports weight loss.
FDA Approvals (as of 2025)
- Ozempic (0.5–2.0 mg): For type 2 diabetes, heart disease risk reduction, and slowing diabetic kidney disease.
- Wegovy (up to 2.4 mg): For weight loss in patients with obesity or overweight and a related health issue.
Benefits
- Lowers A1c by ~1.5%–2% in type 2 diabetics
- Weight loss up to 15% of body weight (Wegovy)
- Reduces risk of heart attack, stroke, and kidney failure in high-risk patients
Side Effects
- Common: Nausea, vomiting, diarrhea, constipation
- Serious: Risk of pancreatitis, gallbladder issues, kidney injury, and worsened diabetic eye disease
- Boxed Warning: Rodent thyroid tumors; avoid if personal/family history of MTC or MEN2
Safety
Most issues are GI-related and temporary. Serious risks are rare and preventable with proper screening and hydration.
Cost and Access
High U.S. cost (~$900+ per month). Wegovy often not covered by insurance. Supply shortages and counterfeit products have occurred. FDA warns to use only licensed pharmacies.
Research Outlook
Ongoing studies show strong heart benefits even in non-diabetics. Newer higher doses (7.2 mg) and combination therapies are in development. Additional targets include liver disease, Alzheimer’s, and more.
Bottom Line
Ozempic and Wegovy are reshaping care for diabetes and obesity. Their benefits are significant, but affordability and side effect management remain key challenges for long-term access and success.